Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]

6320 reported adverse events

Drugs of this class: RAMUCIRUMAB

These side effects are most commonly reported by patients taking drugs of the Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] class:

# Side effect Count
0 MALIGNANT NEOPLASM PROGRESSION 817
1 DEATH 614
2 INTERSTITIAL LUNG DISEASE 301
3 NEUTROPENIA 268
4 FEBRILE NEUTROPENIA 265
5 DECREASED APPETITE 234
6 DIARRHOEA 229
7 OFF LABEL USE 218
8 NAUSEA 209
9 DISEASE PROGRESSION 204
See all common reactions for Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]

Drugs of the Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 TUMOUR CAVITATION 9 0.1636
1 TUMOUR PERFORATION 26 0.0818
2 PYOGENIC GRANULOMA 22 0.0472
3 ADENOCARCINOMA METASTATIC 8 0.0388
4 METASTATIC GASTRIC CANCER 10 0.0291
5 TUMOUR HAEMORRHAGE 81 0.0284
6 CHYLOTHORAX 18 0.0250
7 PERFORATION 20 0.0248
8 ANASTOMOTIC COMPLICATION 8 0.0233
9 GASTRIC PERFORATION 53 0.0194
See all enriched reactions for Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC]